• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains

    Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality

    Nutrition and Flavor: Formulating for Modern Product Preferences

    What Do Consumers Know About the Gut Microbiome?

    How Will the European Green Deal Impact Dietary Supplements?
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Lauren Aronson Joins Amin Talati Wasserman, LLP

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise

    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise

    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression

    Fact or Myth: Antioxidants Negatively Impact Iron Absorption
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy

    Lauren Aronson Joins Amin Talati Wasserman, LLP

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise

    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome

    Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise

    Omega-3 Fatty Acids Linked to Reduced Episodes of Depression

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process

    Caffeine-Free Energy Supplement Linked to Alertness, Fatigue Benefits
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Botanic Healthcare LLC

    Verdure Sciences

    Xsto Solutions

    Sabinsa Corporation

    JRS Pharma
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Botanic Healthcare LLC

    Verdure Sciences

    Xsto Solutions

    Sabinsa Corporation

    JRS Pharma
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    FDA Concludes Vinpocetine Ineligible as a Dietary Ingredient

    Federal Register notice follows the recently released NDI guidance.

    FDA Concludes Vinpocetine Ineligible as a Dietary Ingredient
    Related CONTENT
    • ODSP Director Cara Welch Discusses Agency Priorities
    • Sen. Markey Introduces Bill Calling for Stricter GRAS Framework
    • FDCA Preemption of State-Level Misbranding Laws for Structure/Function Ingredient Claims
    • Senate HELP Committee Introduces FDA Safety and Landmark Advancements Act
    • FDA Issues Draft Guidance on NDI Enforcement Discretion
    09.20.16
    The Food and Drug Administration (FDA) has reached a tentative conclusion that vinpocetine is not a dietary ingredient and should be excluded from the definition of a dietary supplement under the Federal Food, Drug, and Cosmetic Act (FDCA). The agency released a Federal Register (FR) notice (Docket No: FDA-2016-N-2523) on Sep. 6 requesting comments related to the regulatory status of vinpocetine and its tentative conclusion until Nov. 7.

    This notice comes on the heels of the recently released redrafted New Dietary Ingredient (NDI) guidance. Additionally, on Oct. 6, 2015, Senator Claire McCaskill (D-MO), the ranking member of the U.S. Senate Special Committee on Aging, called for the FDA to suspend sales of supplements containing vinpocetine pending an investigation.

    The Natural Products Association (NPA), Washington, D.C., called the FDA’s FR notice “unprecedented,” and said the action has major implications. Noting that the first of five successful NDI submissions for vinpocetine dates back to 1997, NPA said the agency has not mentioned any public health concern and has not considered the economic impact on firms that have been lawfully selling the ingredient for almost two decades. 

    “FDA appears to be attempting to shift the burden of demonstrating reasonable expectation of safety for vinpocetine on the industry by using the hook that it can’t qualify as a dietary ingredient,” the association said in a press statement.

    FDA’s notice said vinpocetine is “a synthetic compound that is derived from vincamine, an alkaloid found in the Vinca minor L. plant. Vinpocetine can also be derived from tabersonine, an alkaloid found in Voacanga seeds. According to the information we’ve reviewed, vinpocetine is not a constituent of these plants, or of any other plants. Instead, it is synthetically produced.”

    The agency continued to say that according to a report by NIH’s National Toxicology Program, dietary supplements containing vinpocetine are marketed for uses that include “improvement of brain function, rapid weight loss and/or fat loss, increases in energy, and improvement in visual acuity, memory, and focus. Vinpocetine is also reportedly marketed for uses including the prevention of motion sickness and the treatment of menopausal symptoms, chronic fatigue syndrome, seizure disorders, and hearing and eye disorders. The FDA has not assessed whether vinpocetine is effective for any of these uses.”

    NPA argued that vinpocetine has five acknowledgements from FDA in its NDI database. “This means that vinpocetine has already undergone intense scrutiny five times over by the leading authority on food safety in the U.S. Each time, FDA responded with a letter stating that they had no concerns over the ingredient or the data provided in their safety dossiers. From the FR notice, FDA does not appear to have any clear safety signal based on SAERs (serious adverse event reports) or other means. However, the agency is looking to remove the ingredient via a rendering that they have been silent on for approximately 20 years regarding the ingredient’s status.”

    Daniel Fabricant, CEO and executive director of NPA said the agency’s actions constitute a form of double jeopardy. “To go through the regulatory gate a second time is akin to finishing a round of golf and winning but then having to play a second round while someone charges at you while you hit each golf shot. This sets a very bad precedent and is no environment to conduct business in.”

    “The FR notice was also absent any economic impact analysis,” he continued. “There is an economic impact here as firms have been lawfully marketing this ingredient since it was successfully notified in the 90s. Consistent with the statute, is the agency planning to conduct an economic impact analysis? The original economic impact analysis on 21 CFR 190.6 never presented a situation where a properly notified ingredient, considered lawful for a period of time, could be removed instantaneously approximately 20 years ex post facto. It would appear that removal of this ingredient would bear little incremental public health effect (per the notice) but a significant incremental cost associated with the change in regulatory status, which is, by law, generally considered in such actions and how to provide more or other cost-effective alternatives or enforcement discretion. No discussion on enforcement discretion is present either. Why? Is this what responsible industry can expect in the future with other new dietary ingredients?”
    Related Searches
    • Quality & Safety
    • Regulations
    • Dietary Supplements
    Related Knowledge Center
    • Quality & Safety
    • Regulations
    • Dietary Supplements
    Suggested For You
    ODSP Director Cara Welch Discusses Agency Priorities ODSP Director Cara Welch Discusses Agency Priorities
    Sen. Markey Introduces Bill Calling for Stricter GRAS Framework Sen. Markey Introduces Bill Calling for Stricter GRAS Framework
    FDCA Preemption of State-Level Misbranding Laws for Structure/Function Ingredient Claims FDCA Preemption of State-Level Misbranding Laws for Structure/Function Ingredient Claims
    Senate HELP Committee Introduces FDA Safety and Landmark Advancements Act Senate HELP Committee Introduces FDA Safety and Landmark Advancements Act
    FDA Issues Draft Guidance on NDI Enforcement Discretion FDA Issues Draft Guidance on NDI Enforcement Discretion
    Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    MR-10®: A Natural Botanical Ingredient Clinically-Proven to Alleviate Symptoms of Andropause MR-10®: A Natural Botanical Ingredient Clinically-Proven to Alleviate Symptoms of Andropause
    How Will China’s Immunity Gap Impact the Dietary Ingredients Supply Chain? How Will China’s Immunity Gap Impact the Dietary Ingredients Supply Chain?
    Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    Is There Momentum to Modernize DSHEA, or Too Much Division? Is There Momentum to Modernize DSHEA, or Too Much Division?
    NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act NPA Letter Spells Out Perceived Failings of Proposed Dietary Supplement Listing Act
    Dietary Supplement Listing Bill Introduced in Senate Dietary Supplement Listing Bill Introduced in Senate
    Nuseed’s Omega-3 Canola Ingredients Succeed FDA Review For Human, Animal Safety Nuseed’s Omega-3 Canola Ingredients Succeed FDA Review For Human, Animal Safety
    The Nuts and Bolts of FDA’s 2023 Budget Request The Nuts and Bolts of FDA’s 2023 Budget Request
    Hemp and CBD Updates: Industry Still in the Weeds Hemp and CBD Updates: Industry Still in the Weeds

    Related Online Exclusives

    • Breaking News | Dietary Supplements | Industry & Market News | Quality & Safety | Regulations
      ODSP Director Cara Welch Discusses Agency Priorities

      ODSP Director Cara Welch Discusses Agency Priorities

      Facility inspections, NDIs, enforcement, and education are all top-of-mind.
      Mike Montemarano, Associate Editor 07.05.22

    • Breaking News | Regulations | Regulatory News
      Sen. Markey Introduces Bill Calling for Stricter GRAS Framework

      Sen. Markey Introduces Bill Calling for Stricter GRAS Framework

      The new bill would direct the U.S. Food and Drug Administration with creating an office that would reassess whether current GRAS substances are safe.
      06.06.22

    • Dietary Supplements | Regulations
      FDCA Preemption of State-Level Misbranding Laws for Structure/Function Ingredient Claims

      FDCA Preemption of State-Level Misbranding Laws for Structure/Function Ingredient Claims

      If a claim describes the substantiated role a nutrient or dietary ingredient plays in the body, plaintiffs cannot survive a motion for summary judgment.
      By Todd Harrison, Partner; Richard Starr, Associate; and Olisa Onyiuke, Associate, Venable 06.02.22


    • Dietary Supplements | Regulations
      Senate HELP Committee Introduces FDA Safety and Landmark Advancements Act

      Senate HELP Committee Introduces FDA Safety and Landmark Advancements Act

      Legislation includes mandatory product listing provision, yet doesn’t draw support from CRN.
      By Sean Moloughney, Editor 05.31.22

    • Dietary Supplements | Regulations
      FDA Issues Draft Guidance on NDI Enforcement Discretion

      FDA Issues Draft Guidance on NDI Enforcement Discretion

      Amnesty for late NDI notifications is intended to encourage manufacturers and distributors to correct past failures while collecting safety data, FDA said.
      By Sean Moloughney, Editor 05.20.22

    Loading, Please Wait..
    Breaking News
    • BASF Venture Capital and Aqua-Spark invest in Sea6 Energy
    • Lauren Aronson Joins Amin Talati Wasserman, LLP
    • Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    • Vitamin D May Prevent Changes to Liver Enzymes and Lipid Profile After Exhaustive Exercise
    • Omega-3 Fatty Acids Linked to Reduced Episodes of Depression
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • A Growing Herbal Products Market Still Faces Formidable Threats, Challenges
    • Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality
    • Nutrition and Flavor: Formulating for Modern Product Preferences
    • Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains
    • How Will the European Green Deal Impact Dietary Supplements?
    • What Do Consumers Know About the Gut Microbiome?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    BASF Venture Capital and Aqua-Spark invest in Sea6 Energy
    Lauren Aronson Joins Amin Talati Wasserman, LLP
    Vitamin K2 May Ameliorate Polycystic Ovary Syndrome
    Coatings World

    Latest Breaking News From Coatings World

    Ashland Completes Sale of Land in Ajax, Canada
    Chemours Begins Commissioning New Sand Mine in Clay County, FL
    Evonik Increases Production Capacities for ACEMATT Matting Agents
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Preceptis Medical’s Tympanostomy Tube System Cleared for Expanded Indications
    Dyad Medical’s Echocardiogram Application Cleared by FDA
    Hua Shan Appointed to Cerus Corporation Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Grand River Aseptic Manufacturing Completes Phase II Expansion
    WCG Appoints Rahul Bafna Chief Product Officer
    WuXi STA Breaks Ground for New Pharma Mfg. Campus in Middletown, DE
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    SOS Beauty Fills Several Senior Leadership Positions
    Beauty Sales to Higher Income Consumers in U.S. Increase Double-Digits in 2022
    Johnson & Johnson to Discontinue Global Sales of Talc-Based Baby Powder
    Happi

    Latest Breaking News From Happi

    Genemarkers Partners with Sequential Bio to Improve Development of Microbiome-Friendly Skincare Products
    Lysol Pro Solutions Launches Individually-Wrapped Single-Count Lysol Disinfecting Wipes
    Higher Income Consumers Increase Spending on Beauty Products by 14% in 2022: NPD Group
    Ink World

    Latest Breaking News From Ink World

    DuPont Selects 2022 Lavoisier and Pedersen Award Medalists
    Chemours Begins Commissioning Newest Sand Mine in Clay County, FL
    Marabu to Present Safe Inks for Indirect Contact with Food at K 2022
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Simco-Ion Industrial expands application engineering expertise
    Eaglewood to debut Sitexco Label L10 at Labelexpo
    Monadnock Paper Mills earns gold rating from Ecovadis
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Because Market Expands into Retail Stores
    Tranzonic Acquired by Private Investment Firm
    Monadnock Earns EcoVadis Gold Rating
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs VySpine's VyPlate Anterior Cervical Plates
    Moximed Raises $40M for Knee OA Shock Absorber Implant
    Exactech Rolls Out Spartan Stem and Logical Cup
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    DuPont Names 2022 Lavoisier and Pedersen Award Medalists
    Photonic Glasses Give Solar Panels Pleasing Colors
    SEMI Appoints John Cooney to Lead Global Advocacy and Public Policy

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login